Core Insights - AstraZeneca has officially launched its Global R&D Beijing Strategic Center, marking its sixth global and second strategic R&D center in China, aimed at accelerating the translation of early drug research results into clinical development [1] Group 1: Strategic Initiatives - The new center is part of AstraZeneca's strategy to enhance drug development capabilities in China and globally [1] - AstraZeneca has announced collaborations with Cambridge University, Beijing Municipal Science and Technology Commission, Zhongguancun Science Park Management Committee, and Beijing Economic-Technological Development Area Management Committee [1] Group 2: Vision and Goals - AstraZeneca's UK Chairman, Shaun Grady, emphasized the goal of establishing a two-way connection between Beijing and Cambridge University, aiming for innovation that serves both local and global needs [1] - The initiative reflects AstraZeneca's view of China as a significant internal source of innovation while also pursuing external collaborations [1]

Core Viewpoint - ST HuLuWa (605199.SH) aims to enhance its core competitiveness and accelerate drug development by integrating R&D resources and sharing R&D risks through a technical cooperation agreement with related parties [1] Group 1: Company Actions - The company held a special meeting of independent directors and an extraordinary board meeting on October 17, 2025, to approve the proposal for signing a technical cooperation development contract [1] - The expected total R&D cost for the projects "Ondansetron Oral Soluble Film" and "Ibutamoren Right-Arm Injection Concentrate Solution" is budgeted to not exceed 11.25 million yuan [1] - Following board approval, the company will sign a technical cooperation development contract with Kang Lianxian to jointly develop the aforementioned projects [1]

Core Insights - Zealand Pharma has had an exciting year, highlighted by a significant partnership with Roche, which was established in March and has progressed rapidly towards Phase III for the petrelintide asset [3]. Company Overview - David Kendall has been with Zealand Pharma for 5 years and serves as the Chief Medical Officer, bringing prior experience from Eli Lilly and Amylin Pharmaceuticals [2]. Partnership Highlights - The partnership with Roche is a focal point for Zealand Pharma, with rapid advancements in their metabolism portfolio and the petrelintide asset [3].